Pharmaceuticals, Biotechnology and Life Sciences
Arix Bioscience said Wednesday that its portfolio company Artios Pharma Ltd, has entered in-licensing agreement of a small-molecule ATR inhibitor programme from The University of Texas MD Anderson Cancer Center and ShangPharma.
Arix Bioscience has invested in new portfolio company Imara, Inc, thus adding to its novel therapeutics for chronic treatment of Sickle Cell Disease (SCD) and other hemoglobinopathies options.
Arix Bioscience has led an oversubscribed $30 million Series F financing round for a clinical biotechnology company Atox Bio.
Arix Bioscience has co-led an oversubscribed Series A financing round raising $29 million for PreciThera, a new Arix Group Business focused on developing novel biological therapeutics to treat orphan bone diseases.
Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising $45 million.
Arix Bioscience on Friday said that its new business group, Iterum, has raised $65 million by closing a Series B investment round. “Arix is delighted to have led this $65m funding round comprising many of the biotech sector’s leading specialist investors,” said…
Arix Bioscience, the Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MPI), and the University of Leeds have signed agreement to develop new therapeutics for metabolic diseases based on the discoveries from these organisations.
Arix Bioscience and Takeda will work together to combine complementary skills and experience across important therapeutic areas in a strategic deal.
Arix Bioscience’s issued ordinary shares have on Wednesday been admitted to the Official List of the UK Listing Authority and to trading on the London Stock Exchange’s main market for listed securities under the ticker “ARIX”.
London-listed healthcare company Arix Bioscience said on Friday it raised £100 million in its Initial Public Offering, with total market capitalisation at Admission to be £187 million.